# US 2017/0283427 A1 · Compounds for the inhibition of cyclophilins and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0283427 A1
- Document ID: US20170283427A1
- Status: Published application
- Kind: A1
- Application number: 15/474,193
- Filed: 2017-03-30
- Published: 2017-10-05
- Earliest claimed: 2016-03-31
- Assignees: Merck Patent GmbH
- Applicants: Merck Patent GmbH
- Inventors: Catherine JORAND-LEBRUN; Theresa L. JOHNSON; Ulrich GRAEDLER; Xuliang JIANG; Santosh KULKARNI
- Web page: https://patentgrep.com/patent/US20170283427A1

## CPC

- C07D 491/18: Bridged systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 21/02: Muscle relaxants, e.g. for tetanus or cramps
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/12: Antivirals
- A61P 33/00: Antiparasitic agents
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 209/48: with oxygen atoms in positions 1 and 3, e.g. phthalimide
- C07D 209/70: containing carbocyclic rings other than six-membered
- C07D 209/72: 4,7-Endo-alkylene-iso-indoles
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 491/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cyclophilins, and for the treatment of cyclophilin-related disorders.

## Claims

### Claim 1

A compound of formula I,
or a pharmaceutically acceptable salt thereof, wherein:
Ring A is C3-10 aryl, which is optionally substituted;
each R′ is independently —R, halogen, -haloalkyl, -hydroxyalkyl, —OR, —C(O)R, —CO2R, —C(O)N(R)2, —NRC(O)R, or —N(R)2;
each R1 is independently —H or C1-6 aliphatic which is optionally substituted;
each R1a is independently —H or C1-6 aliphatic which is optionally substituted;
or R1 and R1a taken together with the atom to which they are attached form a 3-7 membered carbocyclic ring optionally having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, which is optionally substituted;
each R2 is independently —H or C1-6 aliphatic which is optionally substituted;
each R2a is independently —H or C1-6 aliphatic which is optionally substituted;
X is CH2 or O; or X and the bonds attached to X are absent;
each R is independently hydrogen, C1-6 aliphatic, C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted; or
two R groups on the same atom are taken together with the atom to which they are attached to form a C3-10 aryl, a 3-8 membered saturated or partially unsaturated carbocyclic ring, a 3-7 membered heterocylic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; each of which is optionally substituted;
m is 1 or 2;
n is 1 or 2; and
p is 1, 2, 3, 4, or 5.

### Claim 2 (depends on 1)

The compound of claim 1, wherein Ring A is phenyl.

### Claim 3 (depends on 2)

The compound of claim 2, wherein Ring A is phenyl which is fused with a 7-9 membered saturated or partially unsaturated heterocyclic mono- or bicyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; which is optionally substituted.

### Claim 4 (depends on 1)

The compound of claim 1, wherein each R′ is independently —R, —OR, or —N(R)2.

### Claim 5 (depends on 4)

The compound of claim 4, wherein each R′ is independently H, -Me, -Et, —OH, or —NH2.

### Claim 6 (depends on 1)

The compound claim 1, wherein Ring A is

### Claim 7 (depends on 1)

The compound of claim 1, wherein X is CH2.

### Claim 8 (depends on 1)

The compound of claim 1, wherein X is O.

### Claim 9 (depends on 1)

The compound of claim 1, wherein X, and the bonds attached to X, are absent.

### Claim 10 (depends on 1)

The compound of claim 1, wherein each R1 is independently —H or -Me.

### Claim 11 (depends on 1)

The compound of claim 1, wherein R1 and R1a taken together with the atom to which they are attached form a cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, each of which is optionally substituted.

### Claim 12 (depends on 1)

The compound of claim 1, of formula II:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 1)

The compound of claim 1, of formula V:
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

The compound of claim 1, of formula VI:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

The compound of claim 1, of formula VII:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

The compound of claim 1, selected from Table 1.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, and a pharmaceutically acceptable adjuvant, carrier, or vehicle.

### Claim 18 (depends on 1)

A method for treating a cyclophilin-mediated disease or disorder in a subject in need thereof, comprising the step of administering to said subject a compound of claim 1.

### Claim 19 (depends on 18)

The method of claim 18, wherein the disease or disorder is selected from viral infections, inflammation, neurologic disorders, cardiac failure and cancer.

### Claim 20 (depends on 18)

The method of claim 18, wherein the disease or disorder is selected from Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Dementia, Multiple Sclerosis, and Huntington's disease.
